Studies with SGLT2 inhibitors primarily focused on renal parameters in patients with chronic kidney disease with/without type 2 diabetes mellitus

Overview

At present are ongoing or finished some clinical studies with SGLT2 inhibitors primarely focused on renal outcomes in patients with chronic kidney disease (CKD) with or without type 2 diabetes mellitus. Canagliflozin in CREDENCE study in patients with type 2 diabetes mellitus and CKD stages 2–3b reduced risk of primary renal outcome (doubling of the serum creatinine level, end-stage kidney disease, death from renal or cardiovascular causes) by 30 % in comparison with placebo. Occurence of primary outcome – progression of CKD (defined as sustained decline in the estimated GFR of ≥ 50 % or end-stage kidney disease), or death from cardiovascular or renal causes – was by administration of dapagliflozin in study DAPA-CKD in patients with or without type 2 diabetes decreased by 39 %. Study EMPA-KIDNEY with empagliflozin is still ongoing. Current ADA/EASD guidelines recommend SGLT2 inhibitors in patients with CKD and GF ≥ 0,5 ml/s or albuminuria (mainly macroalbuminuria) as second line therapy after metformin independently of baseline or individualised HbA_1c target.

Keywords:

canagliflozin – dapagliflozin – empagliflozin – study CREDENCE – study DAPA-CKD –study EMPA-KIDNEY